YBL-031

N/A

Report date: 2026/03/19 17:01:31

Base Information

Drug NameYBL-031

Drug Alias NameYBL-031ACE-18

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-Epidermal growth factor receptor erbB1

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesY-biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesY-biologics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A